Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe

Giuseppe Curigliano • 9 Dec 2021
SABCS 2021
Breast Cancer
PROCURE RxPONDER

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, discusses the PROCURE project, a survey across European investigators about use of genomic signatures to make decisions about adjuvant chemotherapy use in early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Consultation fees from Pfizer, Roche, Astra Zeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Lilly; Ellipsis, Merck

More from Giuseppe Curigliano

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
Future research directions for breast cancer
2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021
Highlights from the St. Gallen Consensus Panel
3:10
Highlights from the St. Gallen Consensus Panel
Giuseppe Curigliano • 24 Mar 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals